These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Author: Karls S, Shah H, Jacene H.
    Journal: Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616.
    Abstract:
    FDG-PET/CT is an established first-line diagnostic imaging tool used in the staging of most lymphomas and for post-therapy response assessment in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Many of the subtypes of lymphoid neoplasms classified by the World Health Organization demonstrate significant FDG-avidity or uptake; however, many guidelines and Lugano classification do not recommend the use of FDG-PET/CT in assessing response to therapy for these non-HL, non-DLBCL subtypes as a first-line diagnostic tool. This article reviews the role of FDG-PET/CT in the evaluation of the other most common "FDG-avid" lymphomas than HL and DLBCL, the role of FDG-PET/CT before autologous stem cell transplant, and for post-treatment follow-up. Follicular lymphoma is most commonly FDG-avid with a wide range of uptake that generally correlates with the histologic grade, a major determinant of aggressiveness and prognosis. FDG-PET/CT is more sensitive and specific than CT for detecting residual disease post therapy for both aggressive and indolent follicular lymphoma. Post-treatment FDG-PET/CT for follicular lymphoma has significant prognostic value, that is, better predicts progression-free and overall survival than does conventional post-treatment assessment with CT. FDG-PET/CT is useful in the staging of mantle cell lymphoma, a very aggressive, incurable subtype of lymphoma; however, data show mixed results on the benefits of FDG-PET/CT over conventional CT assessment in post-therapy response evaluation. Peripheral T-cell lymphomas, a rare aggressive group of T-cell lymphomas, are often FDG-avid. Post-therapy FDG-PET/CT results have major prognostic value and therapeutic implications in many subtypes of peripheral T-cell lymphomas. Post-treatment FDG-PET/CT is superior to conventional CT for determining chemosensitivity of lymphoma, and therefore is better able to predict which patients will have a greater benefit or outcome with autologous stem cell transplant. There are mixed data on the value of FDG-PET/CT for surveillance after treatment because of high reported false-positive rates and accuracy that depends on the duration or timing of surveillance and the subtype of lymphoma.
    [Abstract] [Full Text] [Related] [New Search]